Corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) are rare, rapidly progressive 4R-tauopathies with no disease-modifying treatments approved to date. The rarity of these conditions — PSP affects approximately 5-7 per 100,000 people[@espinosa2023], and CBS is even rarer — makes traditional large-scale randomized controlled trials (RCTs) infeasible. This creates a fundamental tension: the patients who need treatments most are too few for conventional trial infrastructure.
N-of-1 and personalized trial designs offer a solution. These approaches individualize treatment evaluation, enabling even single patients to generate meaningful evidence about therapeutic response. Originally pioneered in oncology and rare genetic diseases, the same frameworks apply directly to CBS/PSP, where patient-specific factors — genetic background, tau isoform expression, comorbidities, and baseline disability — dramatically affect treatment response.
This page covers the complete methodology for personalized clinical trials in CBS/PSP, from N-of-1 design principles through iPSC-derived drug screening, compassionate use pathways, regulatory frameworks, and practical case studies from oncology.
An N-of-1 trial is a randomized, double-blind, crossover experiment conducted in a single patient[@guyatt1986]. It compares an investigational treatment to placebo (or an active comparator) in repeated cycles, allowing each patient to serve as their own control. N-of-1 trials provide the highest level of individual evidence — better than case reports, better than observational data — while maintaining scientific rigor.
For CBS/PSP patients, N-of-1 trials address several critical gaps:
A CBS/PSP N-of-1 trial typically follows this structure:
Primary endpoints must be sensitive to individual change over short periods. Recommended measures include:
| Domain | Instrument | Rationale |
|---|---|---|
| Motor function | PSPRS (PSP)[@golbe2014], CBSI (CBS)[@matsuo2009] | Standardized, validated |
| Gait/balance | Tinetti POMA[@tinetti1986], 10m walk | Sensitive to change |
| Cognition | FAB[@dubois2000], MoCA[@nasreddine2005] | Captures frontal/executive decline |
| Biomarker | Plasma p-tau217[@janelidze2020], NfL[@bublok2022] | Objective, liquid measure |
| Caregiver burden | Zarit Burden Interview[@zarit1980] | Patient-reported outcome |
N-of-1 trials use within-patient comparison, typically via:
For a single patient, p-values are interpreted with caution. Even with N-of-1, a treatment demonstrating consistent, meaningful benefit across 2-3 cycles provides strong evidence for individual use, especially when corroborated by biomarker changes.
N-of-1 trials are not appropriate for all scenarios:
Induced pluripotent stem cells (iPSCs) derived from a patient's own cells (typically fibroblasts or blood) can be differentiated into cortical neurons, dopaminergic neurons, or astrocytes[@takahashi2007]. These patient-specific neurons retain the individual's genetic background and can manifest disease-relevant phenotypes — including tau aggregation, mitochondrial dysfunction, and synaptic loss — in a dish.
For CBS/PSP, iPSC screens offer:
The field has made significant progress generating 4R-tauopathy models from iPSCs:
| Platform | Throughput | Readout | Application |
|---|---|---|---|
| High-content imaging | ~1000 wells/ plate | p-tau intensity, neurite morphology, cell viability | Primary screening |
| Flow cytometry | ~10,000 cells/sample | Tau phosphorylation state, apoptosis markers | Validation |
| Seahorse bioenergetics | 96-well | OCR, ECAR for mitochondrial function | Mechanistic |
| Multi-electrode array (MEA) | 768 channels | Neuronal firing rate, network synchronization | Functional |
iPSC screening for CBS/PSP remains in the translational research phase:
However, for patients who can wait 3-6 months and whose families can finance screening, iPSC data dramatically increases the probability of choosing an effective treatment for their N-of-1 trial or compassionate use request.
Blood and CSF biomarkers enable real-time adaptation of trial enrollment and dose selection without invasive procedures:
| Biomarker | Source | What It Measures | Application |
|---|---|---|---|
| p-tau217 | Plasma/CSF | Neurofibrillary tangle burden[@janelidze2020] | Enrollment enrichment, response |
| p-tau181 | Plasma/CSF | Early tau pathology[@karikari2020] | Screening, baseline stratification |
| NfL | Plasma/CSF | Neuroaxonal injury[@bublok2022] | Progression rate, futility |
| YKL-40 | CSF | Neuroinflammation[@quetglat2019] | Microglial activation state |
| Alpha-synuclein | CSF | Co-pathology (PD overlap)[@s要做an2021] | Patient exclusion |
Using biomarker thresholds to adapt trial enrollment mid-study:
Basket trial designs — pioneered in oncology for molecularly-defined cohorts — apply naturally to 4R-tauopathies:
This approach maximizes the analyzable population by removing clinical syndrome as the primary enrollment criterion.
The FDA provides three pathways for access to investigational treatments outside clinical trials:
| Pathway | When to Use | Requirements | Timeline |
|---|---|---|---|
| Individual expanded access (EA1) | Single patient, not in trial | Physician request, IRB approval, manufacturer consent | 1-4 weeks |
| Intermediate population (EA2) | Small group, serious condition | Protocol, IRB,IND exemption | 1-3 months |
| Treatment IND/BAA (EA3) | Large group, life-threatening | IND/IMPD filed, sufficient safety data | 3-6 months |
| Right-to-Try Act (2018) | Terminal illness | No FDA approval needed beyond Phase 1, patient exhausted standard options | Varies |
For CBS/PSP patients, the most relevant pathway is individual expanded access (EA1), which allows a treating physician to request a single-patient IND for a patient who:
The treating physician submits Form FDA 3926 (individual new drug IND) to the FDA, which must respond within 30 days (typically within 1-2 weeks for serious conditions). Key elements:
Several investigational agents have been used via expanded access in tauopathy patients:
| Jurisdiction | Pathway | Key Differences |
|---|---|---|
| FDA (US) | Individual IND, Right-to-Try | FDA can require reporting; Right-to-Try removes FDA role |
| EMA (EU) | Named Patient Use, Compassionate Use | Requires member state approval; EMA opinions non-binding |
| Japan (PMDA) | Special Approval for Health Needs | 1-2 month timelines; language barriers |
| UK (MHRA) | Early Access to Medicines Scheme (EAMS) | Industry-sponsored; public health interest determination |
Single-patient (n-of-1) trials conducted outside a formal IND require IRB oversight to protect the patient and establish ethical legitimacy. Most US academic medical centers have established single-patient trial IRB pathways:
Expedited review (not full board): Single-patient protocols can often be reviewed by the IRB chair or designee under the "minimal risk, minor change" category, reducing review time from 30+ days to 3-7 days.
The single-patient IRB protocol should include:
A 65-year-old patient with CBS, MAPT P301L mutation, elevated plasma p-tau217, and progressive motor decline:
N-of-1 trials in CBS/PSP raise specific ethical considerations beyond standard clinical trial ethics:
Vulnerable Population Protection: CBS/PSP patients have progressive cognitive and motor decline, potentially impairing informed consent capacity over time. The ethical framework must:
Therapeutic Misconception Risk: Patients with limited life expectancy may over-interpret the prospects of benefit from an investigational approach. Informed consent documents must clearly distinguish:
Equity and Access: Personalized N-of-1 trials are resource-intensive and may only be accessible to patients with financial means or insurance coverage:
Post-Trial Obligations: What happens after the N-of-1 concludes?
Data Use and Transparency: Results from N-of-1 trials should be shared to advance collective knowledge:
CBS/PSP pathophysiology involves multiple convergent mechanisms — tau aggregation, neuroinflammation, mitochondrial dysfunction, proteostatic failure. Monotherapy targeting a single mechanism is unlikely to arrest disease. Combination therapy raises the stakes for trial design:
The accelerated approval pathway allows FDA approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with post-marketing confirmation. For CBS/PSP:
When combining multiple investigational agents:
A clinical pharmacology review by the FDA is required before combining multiple investigational new drugs (INDs) in a single patient or trial.
Oncology has pioneered personalized medicine approaches that directly inform CBS/PSP strategy.
Background: Vemurafenib (BRAF V600E inhibitor) was tested in melanoma patients with the BRAF mutation[@chapman2011]. Initial N-of-1 dose-escalation studies in selected patients established proof of concept. The subsequent BRIM-3 trial led to accelerated FDA approval in 2011, with confirmatory Phase 4 data.
Relevance to CBS/PSP: Similarly, MAPT mutation carriers represent a molecularly-defined subpopulation within the PSP/CBS spectrum. An agent targeting the mutant tau protein would first demonstrate efficacy in this subgroup before broader enrollment.
Background: Pembrolizumab (anti-PD-1) received accelerated approval for tumors with PD-L1 expression ≥50%[@topalian2016]. The KEYNOTE-001 trial used biomarker-driven enrichment — patients were stratified by PD-L1 expression, and the treatment effect was dramatically larger in high-expression patients. Subsequent trials confirmed this finding and expanded the indication.
Relevance to CBS/PSP: Plasma p-tau217 and CSF NfL serve as analogous biomarkers for tauopathy trials. Enriching for high biomarker expressing patients could double the signal-to-noise ratio in early trials.
Background: Larotrectinib received accelerated approval for tumors harboring NTRK gene fusions regardless of tissue of origin[@drilon2018]. This "tissue-agnostic" basket trial enrolled based on molecular alteration, not cancer type. The ORR was 75% across 17 tumor types.
Relevance to CBS/PSP: Similarly, a tau aggregation inhibitor might be effective across the CBS/PSP/FTD spectrum based on the shared 4R-tau pathology, regardless of the clinical syndrome label.
Background: Following the Right-to-Try Act, oncology patients with exhausted options have accessed investigational drugs directly through physicians, without FDA involvement. Reports from the Goldwater Institute documented hundreds of patients accessing drugs via this pathway.
Relevance to CBS/PSP: CBS patients with median survival of 6-7 years have exhausted standard treatment options. Right-to-try provides a direct route to investigational agents, though without FDA oversight the safety data collection is less rigorous.
| Phase | Duration | Key Activities |
|---|---|---|
| Patient identification and enrichment | 2-4 weeks | Genetic testing, biomarker screening, iPSC generation if applicable |
| IRB protocol preparation and review | 2-4 weeks | Protocol writing, informed consent drafting, IRB submission and review |
| Drug procurement and formulation | 2-8 weeks | Manufacturer negotiation, placebo matching, compounding |
| Baseline period and randomization | 1-2 weeks | Assessments, randomization, blinded drug preparation |
| Crossover periods | 12-20 weeks | Active treatment and placebo periods with washout |
| Final assessment and analysis | 2-4 weeks | Unblinding, statistical analysis, clinical interpretation |
| Total | 4-8 months | From patient identification to result |
| Phase | Duration | Key Activities |
|---|---|---|
| Patient cell collection | 1-2 weeks | Skin biopsy or blood draw |
| Reprogramming | 4-6 weeks | Yamanaka factor delivery, colony picking |
| Characterization | 2-4 weeks | Pluripotency validation, mycoplasma testing |
| Neuronal differentiation | 8-12 weeks | Cortical neuron differentiation protocol |
| Phenotype validation | 2-4 weeks | Tau expression, functional assays |
| Drug screening | 4-8 weeks | Dose-response, high-content imaging |
| Analysis and report | 2-4 weeks | Data interpretation, clinical recommendations |
| Total | 6-9 months | From biopsy to actionable results |
| Component | Cost Range | Notes |
|---|---|---|
| Single-patient IRB protocol and review | $5,000-20,000 | Institutional fees vary widely |
| Drug procurement (repurposed agent) | $0-10,000 | Often available at low cost for approved drugs |
| Drug procurement (investigational) | $10,000-100,000+ | Depends on manufacturer willingness |
| Clinical outcome assessments | $5,000-15,000 | For 2-3 crossover periods |
| iPSC reprogramming and screening | $50,000-200,000 | Full pipeline per patient |
| Biomarker testing (plasma/CSF) | $2,000-10,000 | Per timepoint |
| Total N-of-1 trial | $20,000-150,000 | Without iPSC screen |
| Total with iPSC screen | $70,000-350,000 | Comprehensive personalized approach |